|
| Study | Year | Country | Design | Sample size | Sample composition | Use of gender affirming hormone therapy | Psychiatric diagnosis | Main result |
|
| Abubucker et al. [10] | 2020 | USA | Case report | 1 | Transgender female to male | Yes | BPAD | Drug interaction between remifentanil and exogenous testosterone |
| Tran et al. [11] | 2016 | USA | Case report | 1 | Transgender male to female | Yes | MDD | Drug interaction between exogenous oestrogen and succinylcholine |
| Mormando et al. [15] | 2020 | USA | Case series/retrospective chart review | 6 | Sexual identity: four males, two females | Yes, in 3 (2 estradiol and 1 testosterone) | MDD, gender dysphoria, PTSD, generalised anxiety disorder, obsessive compulsive disorder, and substance use disorder | ECT reduced depressive symptomatology and acute suicidality |
| Coffey and Stevens [9] | 2016 | USA | Case report | 1 | Transgender female to male | Yes | MDD | Safe and effective ECT use in a transgender female to male patient |
| Luccarelli et al. [13] | 2021 | USA | Case series | 19 | Patients who selected “other” for their gender:
Nonbinary 9
Agender 6
Demiboy 2
Transmasculine 1
Transgender female 1
Transgender male 1
Androgynous 1
Transalienation 1
Genderqueer 1 | No | MDD, BPAD, and “other” | ECT was associated with a decrease in depressive symptoms as measured by the QIDS (quick inventory of depressive symptomatology) |
| Sauvaget et al. [12] | 2023 | France | Case report | 1 | Transgender female to male | No | MDD | tDCS (transcranial direct current stimulation) and antidepressant combination therapy used to treat MDD in a transgender female to male patient |
| Oka et al. [14] | 2022 | USA | Case series/retrospective chart review | 59 | Included lesbian, gay, bisexual, and “other” (LGBQ) individuals:
Female 27
Male 16
Transgender female 5
Transgender male 3
Other 5
Choose not to disclose 3
Nonbinary 0
Transgender individuals = 8 | No | MDD (n = 41)
BPAD (n = 15)
Schizophrenia or schizoaffective disorder (n = 3) | Compared outcomes of LGBTQ and control sample (n = 441) with mood disorders receiving ECT. Found that patients experienced clinically significant improvement with ECT regardless of sexual orientation or gender identity |
| Johnstone et al. [8] | 1999 | United Kingdom | Phenomenological qualitative study | 20 | Transgender female to male | No | Not specified | Explored psychological reactions consumers had to ECT |
|
